VIA
AVBP icon

Virtus Investment Advisers’s ArriVent BioPharma AVBP Stock Holding History

Virtus Investment Advisers’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$372K Sell
10,714
-451
-4% -$13.3K 0.09% 323
2026
Q1 		$258K Buy
11,165
+271
+2% +$6.12K 0.07% 308
2025
Q4 		$219K Buy
10,894
+6,078
+126% +$127K 0.06% 364
2025
Q3 		$88.9K Buy
4,816
+837
+21% +$16.4K 0.03% 429
2025
Q2 		$86.6K Sell
3,979
-2,369
-37% -$49.2K 0.03% 398
2025
Q1 		$117K Buy
+6,348
New +$155K 0.03% 397

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Virtus Investment Advisers's AVBP Position: Q2 2026 in Review

Virtus Investment Advisers reduced its ArriVent BioPharma (AVBP) stake by 4% in Q2 2026, selling an estimated $13.3K and leaving 10,714 shares worth $372K. The position accounts for 0.09% of the portfolio, ranked #323.

Virtus Investment Advisers first reported a position in AVBP in Q1 2025 and has held it in 6 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Virtus Investment Advisers held 10,714 shares of ArriVent BioPharma worth $372K as of Q2 2026.
  • Virtus Investment Advisers sold 451 ArriVent BioPharma shares in Q2 2026, an estimated $13.3K.
  • ArriVent BioPharma made up 0.09% of Virtus Investment Advisers's portfolio in Q2 2026, its #323 holding.
  • Virtus Investment Advisers first reported a position in ArriVent BioPharma in Q1 2025 and has held it in 6 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.